Influenza B is a serious illness that can be dangerous, particularly for children, older adults, and people with chronic health conditions. While it’s sometimes perceived as the “milder” flu compared to influenza A, the mortality rates for hospitalized patients are nearly identical: about 7% for influenza B versus 8% for influenza A at 30 days, and 11% for both types at 90 days. The difference in reputation comes partly from the fact that influenza B causes fewer total infections each season, not that each individual case is less severe.
How Influenza B Compares to Influenza A
In a cohort study of over 500 hospitalized flu patients (median age 74), influenza B and influenza A produced strikingly similar outcomes. Ninety-day mortality was 11% for both types. Influenza A did lead to higher rates of pneumonia (19% vs. 10%) and more frequent ICU admissions (6% vs. 3%), but influenza B still sent patients to intensive care and still required mechanical ventilation in 2% of hospitalized cases.
The practical takeaway: if you’re sick enough to be hospitalized with influenza B, your risk of a poor outcome is comparable to influenza A. The virus doesn’t deserve a reputation as the “mild” flu.
Why Children Face Elevated Risk
Influenza B poses a particular threat to kids. During the 2024-25 season, 280 influenza-associated pediatric deaths were reported in the United States, a rate of 3.8 deaths per 1 million children. Influenza B accounted for 14% of those deaths (38 children), with the median age at death being 7 years. More than half of the children who died had at least one underlying medical condition, but that also means nearly half did not.
Vaccination status was a striking factor. Among children whose records were available and who were old enough to be vaccinated, 89% had not been fully vaccinated against the flu that season. That’s a gap with real consequences, since vaccination is one of the few tools that can prevent severe illness before it starts.
Life-Threatening Complications
Both influenza A and B can trigger complications that go well beyond a bad cough. The most common serious complication is pneumonia, which develops when the virus damages the lungs directly or when a bacterial infection takes hold in weakened airways. But influenza can also cause inflammation of the heart muscle (myocarditis), the tissue surrounding the heart (pericarditis), and the brain.
Brain complications deserve particular attention. Over 15 seasons of CDC surveillance, 9% of pediatric flu deaths involved encephalopathy or encephalitis, conditions where the brain swells or becomes inflamed. Of those 166 fatal cases, 28% were caused by influenza B. The median age was 6 years. Among children who developed these brain complications, 93% required mechanical ventilation, and roughly a third also developed pneumonia or sepsis. One of the most severe forms, acute necrotizing encephalopathy, can cause rapid and irreversible brain damage.
These complications are rare in absolute terms, but they illustrate why influenza B shouldn’t be dismissed. A straightforward flu infection can, in some cases, escalate quickly.
Timeline of Illness and Contagion
Symptoms of influenza B typically appear about two days after exposure, though the window ranges from one to four days. The virus can be detected in most infected people starting one day before symptoms appear, which means you can spread it before you even know you’re sick. You’re most contagious during the first three days of illness, but viral shedding can continue for five to seven days after symptoms begin. Children and people with weakened immune systems may remain contagious even longer.
How Well the Vaccine Works Against Influenza B
One piece of good news: the flu vaccine tends to work better against influenza B than influenza A in most seasons. During the 2025-26 season, vaccine effectiveness against influenza B outpatient visits was 63% among adults and ranged from 45% to 71% among children and adolescents, depending on the surveillance network. By comparison, effectiveness against influenza A was only about 34% for adults that same season.
Those numbers mean the vaccine won’t prevent every infection, but it significantly reduces your chance of getting sick enough to need medical care. For children, who face the highest risk of severe complications from influenza B, even moderate vaccine effectiveness translates into meaningful protection.
It’s also worth noting that one of the two influenza B lineages, called Yamagata, has likely gone extinct. No confirmed cases have been detected since early 2020, and the sporadic reports since then appear to be lab artifacts or data errors. This simplifies the challenge for vaccine makers, since only the Victoria lineage of influenza B still circulates.
Antiviral Treatment Options
Antiviral medications work against influenza B, but not all are equally effective. The most commonly prescribed antiviral (oseltamivir, sold as Tamiflu) treats both influenza A and B, though clinical data suggest it may be somewhat less effective against B. A newer antiviral, baloxavir, reduced symptom duration in influenza B patients by more than 24 hours compared to oseltamivir in a randomized trial. Both medications work best when started within the first 48 hours of symptoms.
For people at high risk of complications, including young children, adults over 65, pregnant women, and those with chronic conditions like asthma or heart disease, early antiviral treatment can be the difference between recovering at home and ending up in the hospital. If you’re in a high-risk group and develop flu symptoms, starting treatment quickly matters more than waiting to find out whether it’s type A or B.